Please login to the form below

Not currently logged in


This page shows the latest Barhemsys news and features for those working in and with pharma, biotech and healthcare.

Acacia finally gets FDA okay for first product Barhemsys

Acacia finally gets FDA okay for first product Barhemsys

Edison analyst predicts drug could reach $387m at peak. The long tale of Acacia Pharma’s efforts to bring its post-operative nausea and vomiting (PONV) drug Barhemsys to market is ... Edison previously predicted Barhemsys could add another $110m

Latest news

More from news
Approximately 2 fully matching, plus 0 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs


Add my company
Attigo (part of the Mednet Group)

Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...

Latest intelligence

Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Could formulary intelligence be your brand differentiator?
Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...